PCM
SGMT icon

Prelude Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Prelude Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,200
Closed -$58.7K – 1523
2024
Q3 		$58.7K Buy
21,200
+8,900
+72% +$27.4K ﹤0.01% 1201
2024
Q2 		$42.1K Buy
12,300
+2,100
+21% +$9.63K ﹤0.01% 1157
2024
Q1 		$55.3K Buy
+10,200
New +$73.3K ﹤0.01% 1251

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Prelude Capital Management's SGMT Position: Q4 2024 in Review

Prelude Capital Management sold out of Sagimet Biosciences (SGMT) in Q4 2024, closing a stake of 21,200 shares — an estimated $58.7K sold.

Prelude Capital Management first reported a position in SGMT in Q1 2024 and held it in 3 quarters. The position peaked at $58.7K in Q3 2024. 66 funds tracked by Wall St. Rank hold SGMT as of Q4 2024.

  • Prelude Capital Management reported no remaining Sagimet Biosciences position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 21,200 Sagimet Biosciences shares in Q4 2024, an estimated $58.7K.
  • Prelude Capital Management first reported a position in Sagimet Biosciences in Q1 2024 and held it in 3 quarters.
  • Prelude Capital Management's Sagimet Biosciences position peaked at $58.7K in Q3 2024.
  • 66 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.